NASH NATiV3 Study
NASH Trials in Columbus
Centricity Research is currently participating in the NASH NATiV3 study at our Columbus, Ohio location. NASH (Non-Alcoholic SteatoHepatitis) is the form of liver disease that is triggered by what has come to be known as the “Western diet”, characterized especially by high-fat, high-sugar, and processed foods. Among the effects of a prolonged Western diet is fat accumulation in liver cells (steatosis) which is described as Non-Alcoholic Fatty Liver Disease (NAFLD) and can predispose cells to injury.
People who develop NASH often have additional predisposing conditions such as obesity, diabetes, and hypertension. Many people in the early stages of the disease do not have significant symptoms and therefore do not know that they have it. Advances in drug therapy are key to treating this disease at its early stages and preventing further liver damage.
NASH NATiV3 Study
The primary objective of the NATiV3 clinical study is to evaluate the long-term effectiveness and safety of an investigational drug named lanifibranor, in the treatment of a non-cirrhotic liver disease called non-alcoholic steatohepatitis (NASH) fibrosis (stage 2 or 3 indicating the amount of scarring). You may be eligible to participate if you:
- Are at least 18 years old
- Have been diagnosed with NASH
- Cannot have known non-NASH liver diseases including:
- Autoimmune diseases
- Drug induced liver disease
- Alcoholic liver disease
- Active Hepatitis B or C
We now offer individuals with known risk factors of Non-Alcoholic Fatty Liver Disease (NAFLD) a free Fibroscan screening.
Ready to Volunteer?
Volunteer today to see if you qualify for our NASH NATiV3 clinical research study. Qualified volunteers may be compensated for time and travel.